1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag

New CEO of Senzime

MAR

Uppsala, May 3, 2023. Senzime AB (publ) hereby announces that the company's board of directors has decided to appoint Philip Siberg, currently chairman of the board, as the new CEO. Philip takes up his new role immediately and thus replaces Pia Renaudin who has been CEO since February 2019.

Philip Siberg has been chairman of Senzime since 2016 when the company acquired Acacia Designs BV, which Philip was the CEO of. Acacia Designs pioneered the development of the TetraGraph system based on research from Mayo Clinic in the USA, and it’s today Senzime’s main line of business. Philip has solid experience from various CEO and chairman roles within the Life Science industry and especially commercialization of innovations in the US healthcare market. By the appointment of Philip, the Board believes that Senzime has increased chances to succeed with the commercialization that has rapidly commenced in the US, and Philip brings in deep insights into Senzime's product offering, organization, and market.

"I am very honored to be trusted to take on the role of CEO of Senzime. The company has a fantastic product portfolio, organization and market position which is now facing a powerful global growth journey”, said Philip Siberg.

The board would like to express a big thank you to Pia Renaudin for her wholehearted efforts as CEO of Senzime - not least during the COVID-19 pandemic when Senzime managed to carry out a global launch and show sales growth despite extremely difficult market conditions. Pia has worked hard and has been a strong contributor to taking Senzime to the very exciting position the company is in today including recently communicated rapid growth rate.

Adam Dahlberg succeeds Philip Siberg as chairman of the board. Adam is a member of the Crafoord family and thus represents Senzime's largest owner and a more than 20-year commitment to the company.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Paula Treutiger, Head of Communication and IR
Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-03 17:45 CEST.

Attachments

New CEO of Senzime

Datum 2023-05-03, kl 17:45
Källa MFN
Bifogade filer
New CEO of Senzime
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!